We fitted expression of LGALS3 (Fig. 6b) and LGALS3BP (Fig. 6c) against EMT score and arrayed by tumor immune phenotype to find that LGALS3 expression increases alongside the cancer specific EMT signature expression in every tumor immune phenotype and every delineated EMT phase (i.e., EPI, pEMT, and MES). Here, LGALS3 is linked to neoplasm.